New concepts on the therapeutic control of complement anaphylatoxin receptors.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Molecular Immunology

• Publication date

  2017-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.molimm.2017.05.015PMID 28576324
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.

  2017cited by this paper
• Complement in the fundamental processes of the cell.

  2017influential reference
• The Alternative Receptor for Complement Component 5a, C5aR2, Conveys Neuroprotection in Traumatic Spinal Cord Injury

  2017cited by this paper
• Pharmacological inhibition of complement C5a‐C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis

  2017cited by this paper
• Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis.

  2017cited by this paper
• Intranasal C3a treatment ameliorates cognitive impairment in a mouse model of neonatal hypoxic–ischemic brain injury

  2017cited by this paper
• Complement C5aR1 Signaling Promotes Polarization and Proliferation of Embryonic Neural Progenitor Cells through PKCζ

  2017cited by this paper
• Targeting the Dark Horse of complement: the first generation of functionally selective C5aR2 ligands Strapline: Functionally selective C5aR2 ligands discovery

  2016cited by this paper
• Discovery of functionally selective C5aR2 ligands: novel modulators of C5a signalling

  2016influential reference
• Aptamers in Therapeutics.

  2016cited by this paper
• T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4+ T cells

  2016cited by this paper
• Targeting the Dark Horse of complement: the first generation of functionally selective C5aR2 ligands

  2016cited by this paper
• Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions.

  2016cited by this paper
• The Complement C3a Receptor Contributes to Melanoma Tumorigenesis by Inhibiting Neutrophil and CD4+ T Cell Responses

  2016influential reference
• Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis

  2016cited by this paper
• Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study

  2016cited by this paper
• Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation

  2016cited by this paper
• Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists

  2016cited by this paper
• New milestones ahead in complement-targeted therapy.

  2016cited by this paper
• Applying complement therapeutics to rare diseases.

  2015cited by this paper
• Emerging Therapeutic Options in Age-Related Macular Degeneration

  2015influential reference
• NFκB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer's disease.

  2015cited by this paper
• A Commentary On: “NFκB-Activated Astroglial Release of Complement C3 Compromises Neuronal Morphology and Function Associated with Alzheimer’s Disease”. A cautionary note regarding C3aR

  2015cited by this paper
• Complement, a target for therapy in inflammatory and degenerative diseases

  2015cited by this paper
• The Complement Receptor C5aR Controls Acute Inflammation and Astrogliosis following Spinal Cord Injury

  2015cited by this paper
• Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer(®) therapeutics.

  2015cited by this paper
• Is the Complement Activation Product C3a a Proinflammatory Molecule? Re-evaluating the Evidence and the Myth

  2015influential reference
• Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study.

  2014cited by this paper
• Genetic variants in C5 and poor response to eculizumab.

  2014cited by this paper
• Derivation of ligands for the complement C3a receptor from the C-terminus of C5a

  2014cited by this paper
• Neuroprotective effects of argatroban and C5a receptor antagonist (PMX53) following intracerebral haemorrhage

  2014cited by this paper
• Complement anaphylatoxins as immune regulators in cancer

  2014cited by this paper
• FRI0315 First Human Dose of the Anti-C5a Receptor-Targeting, Human Monoclonal Antibody NNC0215-0384 in Patients with Rheumatoid Arthritis: A Phase 1, Randomised, Double-Blind, Single-Dose, Dose-Escalation Trial

  2014cited by this paper
• Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief

  2014cited by this paper
• Brief Report: Complement C5a Promotes Human Embryonic Stem Cell Pluripotency in the Absence of FGF2

  2014cited by this paper
• Potent heterocyclic ligands for human complement c3a receptor.

  2014cited by this paper
• Change in drusen volume as a novel clinical trial endpoint for the study of complement inhibition in age-related macular degeneration.

  2013cited by this paper
• Intracellular Complement Activation Sustains T Cell Homeostasis and Mediates Effector Differentiation

  2013cited by this paper
• Receptor for complement peptide C3a: a therapeutic target for neonatal hypoxic‐ischemic brain injury

  2013cited by this paper
• Neutrophils—A Key Component of Ischemia-Reperfusion Injury

  2013cited by this paper
• C5L2: a controversial receptor of complement anaphylatoxin, C5a

  2013cited by this paper
• Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria

  2013cited by this paper
• A randomized, double‐blind, placebo‐controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis

  2013cited by this paper
• The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization

  2013cited by this paper
• Complement therapy in atypical haemolytic uraemic syndrome (aHUS)

  2013cited by this paper
• Downsizing a human inflammatory protein to a small molecule with equal potency and functionality

  2013cited by this paper
• Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.

  2013cited by this paper
• Complement Inhibition Promotes Endogenous Neurogenesis and Sustained Anti-Inflammatory Neuroprotection following Reperfused Stroke

  2012cited by this paper
• Monoclonal antibodies: magic bullets with a hefty price tag

  2012cited by this paper
• Role of C3a Receptors, C5a Receptors, and Complement Protein C6 Deficiency in Collagen Antibody-Induced Arthritis in Mice

  2012cited by this paper
• The Complement Anaphylatoxin C3a Receptor (C3aR) Contributes to the Inflammatory Response in Dextran Sulfate Sodium (DSS)-Induced Colitis in Mice

  2012cited by this paper
• Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression

  2012cited by this paper
• The complement system: history, pathways, cascade and inhibitors.

  2012cited by this paper
• Th17 Cytokines Are Critical for Respiratory Syncytial Virus-Associated Airway Hyperreponsiveness through Regulation by Complement C3a and Tachykinins

  2011cited by this paper
• Inhibiting the C5-C5a receptor axis.

  2011influential reference
• Collagen Antibody-Induced Arthritis in Mice Complement Protein C6 Deficiency in Role of C3a Receptors, C5a Receptors, and

  2011cited by this paper
• Complement-mediated Regulation Of The IL-17A Axis Is A Central Genetic Determinant Of The Severity Of Experimental Allergic Asthma

  2010cited by this paper
• A Critical Role for C5L2 in the Pathogenesis of Experimental Allergic Asthma

  2010cited by this paper
• Orphan drug: Development trends and strategies

  2010cited by this paper
• Complement-mediated regulation of the interleukin 17A axis is a central genetic determinant of the severity of experimental allergic asthma

  2010cited by this paper
• Aptamers as therapeutics

  2010cited by this paper
• The C5a Receptor (C5aR) C5L2 Is a Modulator of C5aR-mediated Signal Transduction*

  2009cited by this paper
• C3a Receptor Antagonist Attenuates Brain Injury after Intracerebral Hemorrhage

  2009cited by this paper
• Treatment with a C5aR Antagonist Decreases Pathology and Enhances Behavioral Performance in Murine Models of Alzheimer’s Disease1

  2009cited by this paper
• Complement component 5a (C5a).

  2009cited by this paper
• FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

  2008cited by this paper
• Immunology's foundation: the 100-year anniversary of the Nobel Prize to Paul Ehrlich and Elie Metchnikoff

  2008cited by this paper
• Functional roles for C5a receptors in sepsis

  2008cited by this paper
• Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation.

  2007cited by this paper
• Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

  2007cited by this paper
• Complement: a novel factor in basal and ischemia‐induced neurogenesis

  2006cited by this paper
• Increased Potency of a Novel Complement Factor 5a Receptor Antagonist in a Rat Model of Inflammatory Bowel Disease

  2005cited by this paper
• Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial.

  2004cited by this paper
• Comparative anti‐inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury

  2004cited by this paper
• A Potent Human C5a Receptor Antagonist Protects against Disease Pathology in a Rat Model of Inflammatory Bowel Disease 1

  2003cited by this paper
• Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat.

  2002cited by this paper
• Development of C5a receptor antagonists. Differential loss of functional responses.

  1994cited by this paper
• The FASEB Journal • Research Communication Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration

  year unknowncited by this paper

• Granulomatosis with polyangiitis and microscopic polyangiitis: pathogenesis and clinical manifestations

  2025cites this paper
• Complement peptide receptors in GtoPdb v.2025.3

  2025cites this paper
• Knowing the enemy: strategic targeting of complement to treat Alzheimer disease

  2025influential citation
• Fibroblast derived C3 promotes the progression of experimental periodontitis through macrophage M1 polarization and osteoclast differentiation

  2025cites this paper
• Tissue-targeted regulators of complement for amelioration of human disease: rationale and novel therapeutic strategies.

  2025cites this paper
• Cp40-mediated complement C3 inhibition dampens inflammasome activation and inflammatory mediators storm induced by Bitis arietans venom.

  2025cites this paper
• Inhibition of Alternative and Terminal Complement Pathway Components Modulate the Immune Response Against Bacteria and Fungi in Whole Blood

  2025cites this paper
• The complement system: Biology, pathology, and therapeutic interventions.

  2025cites this paper
• Enigmatic Roles of Complement Anaphylatoxin Signaling in Health and Disease

  2025cites this paper
• Disruption of the C5a/C5aR1 axis confers protection against hookworm infection in lung

  2024cites this paper
• Complement System and Adhesion Molecule Skirmishes in Fabry Disease: Insights into Pathogenesis and Disease Mechanisms

  2024cites this paper
• C5aR1 antagonism suppresses inflammatory glial responses and alters cellular signaling in an Alzheimer’s disease mouse model

  2024cites this paper
• The Role of the Complement System in Synaptic Pruning after Stroke

  2024cites this paper
• C5a Serum Levels in Patients with Endometriosis: A Cross-Sectional Study

  2023cites this paper
• Structural insights into agonist-binding and activation of the human complement C3a receptor

  2023cites this paper
• Molecular basis of anaphylatoxin binding, activation, and signaling bias at complement receptors

  2023cites this paper
• Structural biology of complement receptors

  2023cites this paper
• A guide to complement biology, pathology and therapeutic opportunity

  2023cites this paper
• The role of C5a receptors in autoimmunity.

  2023cites this paper
• SARS-CoV-2 spike protein induces lung endothelial cell dysfunction and thrombo-inflammation depending on the C3a/C3a receptor signalling

  2023cites this paper
• C5a drives the inflammatory response with bacterial dose effect by binding to C5aR1 in zebrafish infected with Aeromonas hydrophila.

  2023cites this paper
• Complement peptide receptors in GtoPdb v.2023.1

  2023cites this paper
• Bothrops jararaca Snake Venom Inflammation Induced in Human Whole Blood: Role of the Complement System

  2022cites this paper
• Epigenetic scores for the circulating proteome as tools for disease prediction

  2022cites this paper
• Complement in the Brain: Contributions to Neuroprotection, Neuronal Plasticity, and Neuroinflammation.

  2022cites this paper
• Neutraligands of C5a can potentially occlude the interaction of C5a with the complement receptors C5aR1 and C5aR2

  2022cites this paper
• Differential expression of C5aR1 and C5aR2 in innate and adaptive immune cells located in early skin lesions of bullous pemphigoid patients

  2022cites this paper
• The Complement System: A Potential Therapeutic Target in Liver Cancer

  2022cites this paper
• The global landscape of approved antibody therapies

  2022cites this paper
• Involvement of complement peptides C3a and C5a in osteoarthritis pathology.

  2022cites this paper
• Mitochondrial C3a Receptor Activation in Oxidatively Stressed Epithelial Cells Reduces Mitochondrial Respiration and Metabolism

  2021cites this paper
• The Complement Pathway: New Insights into Immunometabolic Signaling in Diabetic Kidney Disease

  2021influential citation
• Development of Synthetic Human and Mouse C5a: Application to Binding and Functional Assays In Vitro and In Vivo.

  2021cites this paper
• Complement peptide receptors in GtoPdb v.2021.3

  2021cites this paper
• Interaction of Human C5a with the Major Peptide Fragments of C5aR1: Direct Evidence in Support of “Two-Site” Binding Paradigm

  2021cites this paper
• The Complement System in Ovarian Cancer: An Underexplored Old Path

  2021influential citation
• Elucidating the Key Biomarkers and Immune Infiltration in Acne by Integrated Bioinformatics Analysis

  2021cites this paper
• Processed foods drive intestinal barrier permeability and microvascular diseases

  2021cites this paper
• Complement as a powerful "influencer" in the brain during development, adulthood and neurological disorders.

  2021cites this paper
• In Vivo Pharmacodynamic Method to Assess Complement C5a Receptor Antagonist Efficacy.

  2021cites this paper
• Anaphylatoxin Receptor C3AR1 Promotesoptic Nerve Degeneration in DBA/2J Mice

  2020cites this paper
• Editorial: The Role of Complement in Tumors

  2020cites this paper
• Preclinical Pharmacokinetics of Complement C5a Receptor Antagonists PMX53 and PMX205 in Mice

  2020cites this paper
• A nine-gene signature related to tumor microenvironment predicts overall survival with ovarian cancer

  2020cites this paper
• Emerging Insights into the Structure and Function of Complement C5a Receptors.

  2020cites this paper
• Tackling COVID‐19 infection through complement‐targeted immunotherapy

  2020cites this paper
• Pharmacological characterisation of small molecule C5aR1 inhibitors in human cells reveals biased activities for signalling and function.

  2020cites this paper
• Impact of non-proteinogenic amino acids in the discovery and development of peptide therapeutics

  2020cites this paper
• Absence of the C5a Receptor C5aR2 Worsens Ischemic Tissue Injury by Increasing C5aR1-Mediated Neutrophil Infiltration

  2020cites this paper
• Complement activation links inflammation to dental tissue regeneration

  2020cites this paper
• Complement peptide C3a receptor 1 promotes optic nerve degeneration in DBA/2J mice

  2020cites this paper
• Epigenetic scores for the circulating proteome as tools for disease prediction

  2020cites this paper
• Microglial inflammation and phagocytosis in Alzheimer's disease: Potential therapeutic targets

  2019cites this paper
• Endothelial progenitor cell transplantation alleviated ischemic brain injury via inhibiting C3/C3aR pathway in mice

  2019cites this paper
• A novel approach to immunoapheresis of C3a/C3 and proteomic identification of associates

  2019cites this paper
• Complement activation by IgG containing immune complexes regulates the interaction of C1q with its ligands.

  2019cites this paper
• Complement C5a Induces Renal Injury in Diabetic Kidney Disease by Disrupting Mitochondrial Metabolic Agility

  2019cites this paper
• Inflammatory kidney injury in trichloroethylene hypersensitivity syndrome mice: Possible role of C3a receptor in the accumulation of Th17 phenotype.

  2019cites this paper
• Emerging Roles for G-protein Coupled Receptors in Development and Activation of Macrophages

  2019cites this paper
• A rational search for discovering potential neutraligands of human complement fragment 5a (hC5a).

  2019cites this paper
• Analysis of Potential Genes and Pathways Involved in the Pathogenesis of Acne by Bioinformatics

  2019cites this paper
• The Complement Receptor C5aR2: A Powerful Modulator of Innate and Adaptive Immunity

  2019cites this paper
• Complement System Inhibition Modulates the Pro-Inflammatory Effects of a Snake Venom Metalloproteinase

  2019cites this paper
• New insights into the immune functions of complement

  2019cites this paper
• Significance of Complement System in Ischemic Stroke: A Comprehensive Review

  2019cites this paper
• Complementing the Cancer-Immunity Cycle

  2019cites this paper
• Deletion of Biliverdin Reductase A in Myeloid Cells Promotes Chemokine Expression and Chemotaxis in Part via a Complement C5a–C5aR1 Pathway

  2019cites this paper
• Complement Evasion: An Effective Strategy That Parasites Utilize to Survive in the Host

  2019cites this paper
• Inflammation and autoimmunity in pulmonary hypertension: is there a role for endothelial adhesion molecules? (2017 Grover Conference Series)

  2018cites this paper
• Corn dried distillers grains with solubles (cDDGS) in the diet of pigs change the expression of adipose genes that are potential therapeutic targets in metabolic and cardiovascular diseases

  2018cites this paper
• Complement component 5 does not interfere with physiological hemostasis but is essential for Escherichia coli‐induced coagulation accompanied by Toll‐like receptor 4

  2018cites this paper
• Tissue‐targeted complement therapeutics

  2018cites this paper
• Blood‐brain barrier (BBB) and the complement landscape

  2018cites this paper
• New tricks for an ancient system: Physiological and pathological roles of complement in the CNS.

  2018influential citation
• Aptamers that bind to the human complement component receptor hC5aR1 interfere with hC5aR1 interaction to its hC5a ligand

  2018cites this paper
• Serum complement factor C5a in IgG4-related disease

  2018cites this paper
• Role of complement anaphylatoxin receptors in a mouse model of acute burn‐induced pain

  2018cites this paper
• Development and validation of a LC-MS/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice

  2018cites this paper
• The renaissance of complement therapeutics

  2018cites this paper
• Complementing Lung Cancer: How Tumor Cells Co-opt the Host Complement System to Reach Bone.

  2018cites this paper
• Complement: The Emerging Architect of the Developing Brain.

  2018cites this paper
• Novelties in the field of autoimmunity - 1st Saint Petersburg congress of autoimmunity, the bridge between east and west.

  2017cites this paper
• Complement anaphylatoxins C3a and C5a: Emerging roles in cancer progression and treatment.

  2017cites this paper